nci_id,nct_id,official_title,inclusion_indicaInclusionor,description,text,NCIT,NCI-2009-00336,NCT00392327,Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients,Inclusion,Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks,,((C105715 = YES) OR (C105714 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707= YES) AND C25150 > 16 a )) OR ((C70541 = YES) OR (C70542 = YES) OR (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES ) AND (C25150 <= 16 a)),NCI-2009-00470,NCT00632853,Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0-2,,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2009-00595,NCT00719303,"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?",,,,,NCI-2009-00603,NCT00492778,A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus,,,,,NCI-2009-00817,NCT00001337,Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma,,,,,NCI-2009-01057,NCT00576654,"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2011-00312,NCT01012817,"A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy",Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2011-00878,NCT00956007,A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer,Inclusion,Zubrod performance status 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-01915,NCT00887146,N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2011-01972,NCT00983697,A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients,,,,,NCI-2011-01973,NCT00980954,Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy,Inclusion,Zubrod performance status 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-01974,NCT00981656,A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging,Inclusion,Zubrod performance status =< 1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-01975,NCT00980460,Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment,Inclusion,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2011-01987,NCT01013649,A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma,Inclusion,Zubrod performance status 0 or 1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-01992,NCT02085408,"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)",Inclusion,ECOG performance status (PS) 0-3 (restricted to ECOG PS 0-2 if >= 70 years of age),,((C25150 < 70 a) AND ((C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105726 =YES ))) OR ((C25150 >= 70 a) AND (C105722 = YES)  OR (C105723 = YES) OR (C105725 = YES )),NCI-2011-01992,NCT02085408,"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)",Inclusion,Patients must have an ECOG performance status of 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2011-01992,NCT02085408,"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)",Inclusion,Patients must have an ECOG performance status of 0 -2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2011-02000,NCT01042522,"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary",,,,,NCI-2011-02029,NCT01096368,Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years,,,,,NCI-2011-02034,NCT01118026,Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2011-02037,NCT01101451,"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy",,,,,NCI-2011-02073,NCT02589938,"A Phase III Prospective Randomized Trial of Acupuncture for Treatmentof Radiation-Induced Xerostomia in Patients with Head and Neck Cancer",Inclusion,Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2011-02500,NCT01366144,An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 ,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2011-02515,NCT01051635,A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas,Inclusion,The Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60 %),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2011-02539,NCT01226940,A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas,Inclusion,"Patients should have a Karnofsky/Lansky score of greater than or equal to 60; patients who require special assistance due to tumor-related paralysis, but who are out of bed during the day will be considered ambulatory for the purpose of calculating the performance score; patients must be able to communicate any symptoms",,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2011-02592,NCT01386385,"A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)",Inclusion,Patients must have Zubrod performance status 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-02592,NCT01386385,"A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)",Inclusion,Patients must have Zubrod performance status 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2011-02594,NCT01381718,"A Phase II Placebo-Controlled Trial of Modafinil to ImproveNeurocognitive Deficits in Children Treated for a Primary Brain Tumor",,,,,NCI-2011-02599,NCT01190930,Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy),,,,,NCI-2011-02611,NCT01231906,A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma,,,,,NCI-2011-02623,NCT01272037,"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer",Inclusion,Patients must have a performance status of 0-2 by Zubrod criteria,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES),NCI-2011-02660,NCT01275664,Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy,,,,,NCI-2011-02673,NCT01359592,A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL),Inclusion,Zubrod performance status 0-2,,(C19998 = YES ) OR (C19999 = YES) OR (C17846 = YES),NCI-2011-02674,NCT01368588,Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial,Inclusion,Zubrod performance status 0-1 (unless otherwise specified),,(C19998 = YES) OR (C19999 = YES),NCI-2011-03458,NCT01434316,Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2011-03797,NCT02883049,A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations,,,,,NCI-2012-00095,NCT01497444,Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2012-00105,NCT01503632,A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL,,,,,NCI-2012-00112,NCT01503086,Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study,,,,,NCI-2012-00234,NCT01515787,"A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision",Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1 or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2012-00680,NCT01333046,Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma,Inclusion,TREATMENT: Patients with a Karnofsky/Lansky score of >= 50%,,(C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2012-00707,NCT01556243,Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC),Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2012-00719,NCT01573442,Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2012-00860,NCT01587352,A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2012-00864,NCT01585805,"A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with  Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)",Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status:* For Part I (Arm A, B): 0-1 (Karnofsky > 70%)* For Part II (Arm C): 0-2 (Karnofsky >= 60%)",,(C105722 = YES )  OR (C105723 = YES ) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2012-01040,NCT01638533,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2012-01695,NCT01775475,"Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 within 7 days of enrollment,,( C105722 <= 7 d ) OR (C105723 <= 7 d ) OR (C105725 <= 7 d ) OR (C105726 ) <= 7 d),NCI-2012-01712,NCT01695941,A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Karnofsky >= 60%)",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2012-01964,NCT01595061,A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061),,,,,NCI-2012-01967,NCT01602666,Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT),,,,,NCI-2012-01977,NCT01622868,Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG,Inclusion,Karnofsky performance status >= 60 within 21 days prior to study entry,,"(C105712 <= 21 d) OR (C105711 <= 21 d) OR (C105710 <= 21 d) OR (C105709 <= 21 d) OR (C105707 <= 21 d)",NCI-2012-01990,NCT01649089,Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (â‰¤ 2CM) Cervical Cancer,,,,,NCI-2012-01995,NCT01674140,"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.",Inclusion,Patients must have a performance status of 0-2 by Zubrod criteria,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES),NCI-2012-01998,NCT01668719,"A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)",Inclusion,Patients must have Zubrod performance status =< 2,,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2012-02009,NCT01711541,Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2012-02011,NCT01711554,A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma,Inclusion,Lansky (=< 16 years) or Karnofsky (> 16 years) score of at least 50,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)) OR ((C25150 <= 16 a) AND ((C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES))),NCI-2012-02020,NCT01781468,"A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) toReduce Cancer-Related Fatigue in Patients with High Grade Glioma",Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 or 3",,(C105722 = YES) OR (C105723= YES) OR (C105725= YES) OR (C105726 = YES),NCI-2012-02045,NCT01805076,"Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer",,,,,NCI-2012-02057,NCT01730937,Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma,Inclusion,Zubrod performance status 0-2 within 28 days prior to study entry,,( C19998 = YES) OR (C19999 = YES) OR (C17846 = YES )) AND ((C19998 <= 28 d) OR (C19999 <= 28 d ) OR (C17846 <= 28 d ),NCI-2012-02067,NCT01349881,"A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)",Inclusion,Patients must have a Zubrod performance status of 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2012-02078,NCT01789684,"A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of GeneticsServices Among Breast Cancer Patients",,,,,NCI-2012-02608,NCT01863550,"Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)",Inclusion,"STEP II: ECOG performance status 0, 1, or 2 ",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2012-02767,NCT01749397,"A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers",Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2012-02869,NCT01806129,EROS: Engendering Reproductive Health within Oncologic Survivorship,,,,,NCI-2012-02875,NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study,Exclusion,ECOG performance status of 2 or greater,,(C105722 = YES ) OR (C105723 = YES ),NCI-2012-02875,NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study,Inclusion,Patients must have a performance status of 0 or 1 Eastern Cooperative Oncology Group (ECOG) performance status (PS) scale,,(C105722 = YES) OR (C105723 = YES),NCI-2012-03124,NCT01755195,"A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky > 70%),, (C105723 = YES) OR (C105725 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2012-03125,NCT01767194,"A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma",Inclusion,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2012-03173,NCT01089101,A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma,Inclusion,Karnofsky performance scale (KPS for > 16 years [yrs.] of age) or Lansky performance score (LPS for =< 16 years of age) >= 60 assessed within two weeks prior to registration,,"((C25150 > 16 a) AND (C105712 <= 14 d) OR (C105711 <= 14 d) OR (C105710 <= 14 d) OR (C105709 <= 14 d) OR (C105707 <= 14 d)) OR ((C25150 <= 16) AND ((C69422 <= 14 d) OR (C69423 <= 14 d) OR (C69424 <= 14 d) OR (C69425 <= 14 d) OR (C69426 <= 14 d)))",NCI-2012-03198,NCT01872975,A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy,Inclusion,The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2013-00046,NCT01771107,A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma,Inclusion,Karnofsky performance status > 30% (given the aggressiveness of this disease and the often severely debilitated nature of the patients at initial presentation),,"(C105715 = YES) OR (C105714 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)  ",NCI-2013-00370,NCT01220583,A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors,Inclusion,Zubrod performance status 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2013-00426,NCT01824836,A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status between 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2013-00500,NCT01810913,Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck,Inclusion,Zubrod performance status of 0-1 within 14 days prior to registration,,( C19998 = YES OR C19999 = YES ) AND ( C19998 <= 14 d  OR C19999 <= 14 d ),NCI-2013-00595,NCT01817075,Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT),,,,,NCI-2013-00716,NCT00978250,Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU),Inclusion,Karnofsky performance status >= 60%,,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2013-00737,NCT01822496,A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC),Inclusion,Zubrod performance status 0-1 within 14 days prior to registration,,(C19998 = YES OR C19999 = YES) AND (C19998 OR C19999) < 14 d,NCI-2013-00739,NCT01822509,A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-00740,NCT01822522,Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-00805,NCT01244737,A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children,Inclusion,"Karnofsky performance status >= 50 for patients >= 12 years of age; for children < 12 years of age, the Lansky play scale >= 50% can be substituted",,((C25150 > 12 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)) OR ((C25150 <= 12 a) AND ((C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES))),NCI-2013-00826,NCT01841723,A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-00858,NCT01849146,Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma,Inclusion,Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others),,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2013-00875,NCT01901094,A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy,Inclusion,Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2013-00877,NCT01851369,A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Phase I), =< 1 (Phase II)",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-00890,NCT01935934,A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-00998,NCT01881867,A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (ProvengeÂ®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or a Karnofsky performance status of >= 80%,,(C105722 = YES ) OR (C105723 = YES )  OR (C105710 = YES )  OR (C105709 = YES )  OR (C105707 = YES ),NCI-2013-01132,NCT01534598,Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors,Inclusion,Karnofsky performance status >= 60%,,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2013-01272,NCT01897012,A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-01275,NCT01896999,"A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma",,,,,NCI-2013-01320,NCT01902173,Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer,Inclusion,Patients must have Zubrod performance status =< 1,,(C19998 = YES) OR (C19999 = YES),NCI-2013-01320,NCT01902173,Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer,Inclusion,Patients must have Zubrod performance status =< 2,,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2013-01340,NCT01953588,ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2013-01357,NCT01912625,A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-01368,NCT01925131,"A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)",Inclusion,Patients must have Zubrod performance status 0-2,,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2013-01452,NCT00942877,Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status =< 2 for adults, Karnofsky performance status >= 50% for pediatric patients > 10 years of age, and Lansky performance status >= 50 for pediatric patients =< 10 years of age",,((C25150 > 18 a) AND ( C105722 = YES) OR (C105723 = YES) OR (C105725 = YES)) OR (((C25150 > 10) AND (C25150 < 18)) AND (C105713 = YES ) OR (C105712 = YES ) OR ( C105711 = YES) OR (C105710 = YES) OR ( C105709 = YES) OR (C105707 = YES))) OR ((C25150 <= 10 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2013-01474,NCT01273155,Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-01475,NCT01273168,"Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors",Inclusion,The Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-01491,NCT01362803,A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN),Inclusion,"Patients > 16 years of age must have a Karnofsky performance level of >= 70%, and children =< 16 years old must have a Lansky performance of >= 70%; ",,((C25150 > 16 a) AND (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)) OR ((C25150 <= 16) AND ((C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES))),NCI-2013-01496,NCT01391962,"A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-01520,NCT01572493,A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers,Inclusion,Karnofsky performance status >= 70% or Eastern Cooperative Oncology Group (ECOG) =< 1,,"(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)",NCI-2013-01568,NCT01748825,"A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky > 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-01588,NCT01827384,Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors,Inclusion,TREATMENT: Karnofsky performance status >= 70%,,"(C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)",NCI-2013-01588,NCT01827384,Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors,Inclusion,TUMOR BIOPSY SEQUENCING: Karnofsky performance status >= 70%,,"(C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)",NCI-2013-01602,NCT01922076,"A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas",Inclusion,Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age;,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2013-01639,NCT01964300,Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma,Inclusion,Karnofsky performance scale (KPS for >= 16 years [yrs] of age) or Lansky performance score (LPS for < 16 years of age) >= 60 assessed within two weeks prior to registration,,((C25150 > 16a) AND (C105713 <= 14d) OR (C105712 <= 14d) OR (C105711 <= 14d) OR (C105710 <= 14d) OR (C105709 <= 14d) OR (C105707 <= 14d) OR ((C25150 <= 16a) AND (C69421 <= 14d) OR (C69422 <= 14d) OR (C69423 <= 14d) OR (C69424 <= 14d) OR (C69425 <= 14d) OR (C69426 <= 14d)),NCI-2013-01702,NCT02004275,"A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2013-01703,NCT01940809,A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-01748,NCT01947023,A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or Karnofsky>= 60%",,(C105722 = YES ) OR (C105723 = YES )  OR (C105710 = YES )  OR (C105712 = YES) OR (C105711 = YES) OR (C105709 = YES )  OR (C105707 = YES ),NCI-2013-01760,NCT01988571,Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT),Inclusion,Eastern Cooperative Oncology Group (ECOG) 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2013-01850,NCT01993810,Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC,Inclusion,Zubrod performance status 0-1 within 30 days prior to registration,,(C19998 = YES OR C19999 = YES) AND ((C19998 <= 30 d)  OR (C19999 <= 30 d)),NCI-2013-01904,NCT02054741,A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults,,,,,NCI-2013-01999,NCT01946789,"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-02103,NCT01989585,"Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-02167,NCT01979536,"A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)",,,,,NCI-2013-02229,NCT02003222,A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults,Inclusion,CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have an ECOG performance status of 0-3,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105726 = YES),NCI-2013-02229,NCT02003222,A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults,Inclusion,ECOG performance status 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-02229,NCT02003222,A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults,Inclusion,ECOG performance score 0-3,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ) OR (C105726 = YES ),NCI-2013-02229,NCT02003222,A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults,Inclusion,Patients must have an ECOG performance status of 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2013-02238,NCT01896869,"A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",Inclusion,Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky > 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2013-02284,NCT02065687,"A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer",,,,,NCI-2013-02288,NCT02059499,"A Randomized, Phase III Study of Intra-anal Imiquimod 2.5 % vs. Topical 5-Fluorouracil 5% vs. Observation for the Treatment of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Positive Men and Women",Inclusion,Karnofsky performance status of >= 70% or Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,"(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)",NCI-2013-02426,NCT02029950,"A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin, and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 50%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-00115,NCT02015104,"A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVACâ„¢ versus BCG Given Alone in Adults with High Grade Non-muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00416,NCT02070549,A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-00461,NCT02079740,"An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects with KRAS or NRAS Mutation-Positive Advanced Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-00547,NCT02095132,"A Phase 1/2 Study of AZD1775 (MK-1775) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors",Inclusion,Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; ,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2014-00615,NCT02097225,Phase I Study of AT13387 in Combination with Dabrafenib and Trametinib in Patients with BRAF-Mutant Melanoma and Other Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-00616,NCT02152982,A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00620,NCT02101775,"A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-00623,NCT02143726,Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00627,NCT02154490,A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map),Inclusion,Patients must have Zubrod performance status 0-1 documented within 28 days prior to screening/pre-screening registration,,( C19998 <= 28 d) OR (C19999 <= 28 d) ,NCI-2014-00627,NCT02154490,A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map),Inclusion,Patients must have Zubrod performance status 0-1 documented within 28 days prior to sub-study registration,,( C19998 <= 28 d) OR (C19999 <= 28 d) ,NCI-2014-00629,NCT02101788,A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer,,,,,NCI-2014-00631,NCT02101853,Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL),Inclusion,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2014-00634,NCT02101905,Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma,Inclusion,Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others),,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-00635,NCT02135042,Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA),Inclusion,Zubrod performance status 0-1 within 21 days prior to registration,,((C19998 = YES) OR (C19999 = YES)) AND ((C19998 < 21 d) OR (C19999 < 21 d)),NCI-2014-00636,NCT02135419,ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-00640,NCT02255461,"Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors",Inclusion,Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 60,,"((C25150 > 16 a) AND (C105712 <= 14 d) OR (C105711 <= 14 d) OR (C105710 <= 14 d) OR (C105709 <= 14 d) OR (C105707 <= 14 d)) OR ((C25150 <= 16 a) AND (C69422 <= 14 d) OR (C69423 <= 14 d) OR (C69424 <= 14 d) OR (C69425 <= 14 d) OR (C69426 <= 14 d))",NCI-2014-00643,NCT02101944,Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C102408 < 2 AND C38644 = YES AND C3242 = YES) Or (C100417< 60% AND C38644 = YES AND C3242 = YES))  ,NCI-2014-00644,NCT02032823,"A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-00677,NCT02176967,Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-high-risk Neuroblastoma,,,,,NCI-2014-00686,NCT02152137,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00688,NCT02379416,Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00702,NCT02206334,A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases,Inclusion,Zubrod performance status =< 2 within 45 days prior to study registration,,((C19998 = YES) OR (C19999 = YES) OR (C17846 = YES)) AND ((C19998 < 45 d) OR (C19999 < 45 d) OR (C17846 < 45 d)),NCI-2014-00712,NCT02112916,A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy),,,,,NCI-2014-00746,NCT02115282,A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer,Inclusion,Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES) ,NCI-2014-00804,NCT02116777,"A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies",Inclusion,Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age;,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2014-00816,NCT02211755,Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-00849,NCT02200042,"Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma",Inclusion,Zubrod performance status 0-1 within 30 days prior to registration,,(C19998 = YES OR C19999 = YES) AND (C19998 <= 30 d  OR C19999 <= 30 d ),NCI-2014-00850,NCT02177695,"A Randomized Phase II Study of Co-expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer",Inclusion,Patients must have a Zubrod performance status of 0 or 1,,(C19998 = YES) OR (C19999 = YES),NCI-2014-00852,NCT02190279,A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2,,(C105722=YES) OR (C105723=YES) OR (C105725 = YES),NCI-2014-00907,NCT02133183,Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients,Inclusion,Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others),,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-01028,NCT02249949,"A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2014-01043,NCT02143401,"A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-01047,NCT02143414,"A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Postive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL with Known or Presumed Activating Dastinib-Sensitive Mutations or Kinase Fusions (DSMKF)",Inclusion,Patients must have a Zubrod performance status of 0-2,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES),NCI-2014-01072,NCT02179086,Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma,Inclusion,Karnofsky performance status >= 70 within 28 days prior to step 2 registration,,"(C105711 <= 28 d) OR (C105710 <= 28 d) OR (C105709 <= 28 d) OR (C105707 <= 28 d)",NCI-2014-01106,NCT02152995,"A Phase 2 Study of Trametinib in Combination with Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-01107,NCT02159989,Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-01118,NCT02142803,A Phase 1 Study of MLN0128 and Bevacizumab in Patients with Recurrent Glioblastoma and Other Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-01222,NCT02304458,"A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab",Inclusion,Karnofsky >= 50% for patients > 16 years of age and Lansky >= 60 for patients =< 16 years of age; ,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2014-01223,NCT02166463,A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults,,,,,NCI-2014-01340,NCT02180867,Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754),Inclusion,Karnofsky performance status score >= 70 for patients > 16 years of age,,"((C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES)) AND (C25150 > 16 a)",NCI-2014-01340,NCT02180867,Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754),Inclusion,Lansky performance status score >= 70 for patients =< 16 years of age,,((C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES) AND (C25150 <= 16 a )),NCI-2014-01470,NCT02196181,A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma,Inclusion,"Patients must have Zubrod performance status of 0, 1 or 2",,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2014-01497,NCT02270450,Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction,Inclusion,Patients must have Zubrod performance status of 0-2 within 7 days prior to hospitalization,,(C19998 <= 7 d) OR (C19999 <= 7 d) OR (C17846 <= 7 d),NCI-2014-01507,NCT02201992,A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-01508,NCT02193282,Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-01696,NCT02375204,"A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2014-01747,NCT02224781,A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1,,(C105722 = YES ) OR (C105723 = YES),NCI-2014-01754,NCT02203526,"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) unless due to CNS lymphoma,,,NCI-2014-01810,NCT02364557,A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer,Inclusion,Zubrod performance status =< 2 within 60 days prior to registration,,((C19998 = YES) OR (C19999 = YES) OR (C17846 = YES)) AND ((C19998 < 60 d ) OR (C19999 < 60 d) OR (C17846 < 60 d),NCI-2014-01820,NCT02445391,A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy,Inclusion,ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): ECOG performance status 0 or 1 within 2 weeks prior to randomization,,(C105722 <= 14 d) OR (C105723 <= 14 d) ,NCI-2014-01820,NCT02445391,A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks prior to screening,,( C105722 = <= 14 d ) OR (C105723 <= 14 d ),NCI-2014-01927,NCT02243605,A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients with Relapsed Osteosarcomas and Ewing Sarcomas,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,(C105722 = YES) OR (C105723 = YES),NCI-2014-01984,NCT02298959,A Phase 1 Trial of MK-3475 plus Ziv-Aflibercept in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-02020,NCT02575794,Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma,Inclusion,Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others),,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-02056,NCT02437851,A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons,Inclusion,Participants must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky performance status of 50% or greater),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-02167,NCT02275533,Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial),Inclusion,Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0 or 1 (Karnofsky >= 70%),,(C105722 = YES ) OR (C105723 = YES),NCI-2014-02197,NCT02281760,A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 ,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2014-02266,NCT02339740,A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid,,,,,NCI-2014-02267,NCT02412670,A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma,Inclusion,Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES) ,NCI-2014-02379,NCT02496208,A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,Inclusion,Karnofsky performance status >= 70%,,(C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2014-02380,NCT02306161,"Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma",,,,,NCI-2014-02403,NCT02428192,A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,,(C105722 = YES ) OR (C105723 = YES ),NCI-2014-02405,NCT02438722,"A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)",Inclusion,Patients must have Zubrod performance status of 0 - 2,,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2014-02410,NCT02323880,"A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors",Inclusion,Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; ,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2014-02413,NCT02063828,Reducing Lung Cancer Survivors' Anxiety (RELAX),,,,,NCI-2014-02424,NCT02498600,"Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",,,,,NCI-2014-02474,NCT02317874,A Phase 1 Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-02559,NCT01885455,"Improving Resection Rates Among African Americans with NSCLC (""Southern Lung Cancer Study"")",,,,,NCI-2014-02672,NCT02337517,Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) with GDC-0449 (GDC-0449),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2014-02674,NCT02339571,Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1,,(C105722 = YES ) OR (C105723 = YES),NCI-2015-00030,NCT02360215,A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases,Inclusion,Karnofsky performance status of >= 70 within 28 days prior to Step 2 registration,,(C105711 <= 28 d) OR (C105710 <= 28 d) OR (C105709 <= 28 d) OR (C105707 <= 28 d),NCI-2015-00052,NCT02799485,A Phase II Study of sEphB4-HSA in Kaposi Sarcoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky performance score (KPS) >= 50%,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-00054,NCT02465060,Molecular Analysis for Therapy Choice (MATCH),Inclusion,Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months,,((C105722 = YES) OR (C105723 = YES)) AND (C99547 >= 3 m ),NCI-2015-00121,NCT03047213,"An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation",Inclusion,ECOG performance status =< 2 (Karnofsky >= 60 %),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2015-00127,NCT02535312,"Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 -1 (Karnofsky >= 70%),,(C105722 = YES ) OR (C105723 = YES )  OR (C105711 = YES )  OR (C105710 = YES )  OR (C105709 = YES )  OR (C105707 = YES ) ,NCI-2015-00128,NCT02488967,A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,,(C105722 = YES ) OR (C105723 = YES ),NCI-2015-00130,NCT02359565,"A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors",Inclusion,INCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 70,,"((C25150 > 16 a) AND (C105711 <= 14 d) OR (C105710 <= 14 d) OR (C105709 <= 14 d) OR (C105707 <= 14 d)) OR ((C25150 > 16 a) AND (C69423 <= 14 d) OR (C69424 <= 14 d) OR (C69425 <= 14 d) OR (C69426 <= 14 d))",NCI-2015-00130,NCT02359565,"A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors",Inclusion,INCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 60; ,,"((C25150 > 16 a) AND (C105712 <= 14 d) OR (C105711 <= 14 d) OR (C105710 <= 14 d) OR (C105709 <= 14 d) OR (C105707 <= 14 d)) OR ((C25150 <= 16 a) AND ((C69422 <= 14 d) OR (C69423 <= 14 d) OR (C69424 <= 14 d) OR (C69425 <= 14 d) OR (C69426 <= 14 d)))",NCI-2015-00130,NCT02359565,"A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors",Inclusion,INCLUSION CRITERIA FOR NB-NGG (STRATUM B): Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 70;,,"((C25150 > 16 a) AND (C105711 <= 14 d) OR (C105710 <= 14 d) OR (C105709 <= 14 d) OR (C105707 <= 14 d)) OR ((C25150 > 16 a) AND (C69423 <= 14 d) OR (C69424 <= 14 d) OR (C69425 <= 14 d) OR (C69426 <= 14 d))",NCI-2015-00159,NCT02363283,A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00257,NCT02381548,A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 50%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-00258,NCT02381561,Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2015-00260,NCT02500797,Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma,Inclusion,ECOG performance status 0 or 1,,(C105722 = YES ) OR  (C105723 = YES ),NCI-2015-00260,NCT02500797,Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-00323,NCT02516423,Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy,Inclusion,ECOG performance status 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00323,NCT02516423,Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2015-00324,NCT02521493,Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome,,,,,NCI-2015-00328,NCT02392429,Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging,Inclusion,Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years),,(( C105722 = YES) OR (C105723= YES)  OR (C105725= YES) OR (C105726 = YES) AND (C25150 <= 70 a )) OR ((C105722= YES) OR (C105723= YES) OR (C105725 = YES )  AND (C25150 > 70 a )),NCI-2015-00378,NCT02659800,The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide,Inclusion,Patients must have a Karnofsky performance status (KPS) >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others),,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-00383,NCT02398773,[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer,Inclusion,Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years),,(( C105722 = YES) OR (C105723= YES)  OR (C105725= YES) OR (C105726 = YES) AND (C25150 <= 70 a )) OR ((C105722= YES) OR (C105723= YES) OR (C105725 = YES )  AND (C25150 > 70 a )),NCI-2015-00456,NCT02407405,Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 ,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00461,NCT02408861,A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2015-00537,NCT02588443,Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine for Patients with Newly Diagnosed Resectable Pancreatic Carcinoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-00543,NCT02470091,"Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma",Inclusion,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2015-00545,NCT02417701,A Phase 2 Study of MLN0128 (TAK-228) in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2015-00546,NCT02523014,Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00547,NCT02595424,Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas,Inclusion,Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00606,NCT02446600,"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Inclusion,"Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Karnofsky >= 60%)",,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-00651,NCT02502266,"A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2015-00668,NCT02443077,A Randomized Double-Blind Phase III Study of Ibrutinib during and following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2015-00695,NCT02423057,Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-00741,NCT02453620,"A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) ,NCI-2015-00744,NCT02564198,"A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors",Inclusion,Karnofsky performance status >= 50% for patients > 16 years of age and Lansky >= 50 for patients =<16 years of age; ,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2015-00835,NCT02466971,"A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer",,,,,NCI-2015-00866,NCT02474173,"Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01000,NCT02484430,A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-01001,NCT02484443,"A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma",Inclusion,"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2015-01053,NCT02496663,A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01097,NCT02498613,A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01098,NCT02503709,A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01139,NCT02503722,A Phase 1 Trial of MLN0128 in Combination with AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) after Progression on a Previous EGFR Tyrosine Kinase Inhibitor,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01144,NCT02613364,"A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors",,,,,NCI-2015-01178,NCT02308085,"A Study Evaluating the Pregnancy Outcomes and Safety ofInterrupting Endocrine Therapy for Young Women withEndocrine Responsive Breast Cancer Who Desire Pregnancy",,,,,NCI-2015-01236,NCT02562716,A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma,Inclusion,Patients must have a Zubrod performance status of 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2015-01270,NCT02520778,A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01271,NCT02520791,A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01348,NCT02490878,Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases,Inclusion,Karnofsky performance status >= 60%,,(C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01408,NCT02535325,A Phase I Study of Methoxyamine Combined with Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status < 2,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01411,NCT02535338,A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01548,NCT02635009,Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer,Inclusion,Zubrod performance status 0-2 within 30 days prior to Step 1 registration,,((C19998 = YES) OR (C19999 = YES) OR (C17846 = YES)) AND ((C19998< 30 d) OR (C19999< 30 d) OR (C17846 < 30 d)),NCI-2015-01640,NCT02568553,A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01642,NCT02567409,A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma,Inclusion,Karnofsky >= 70% (Eastern Cooperative Oncology Group [ECOG] performance status 0-1),,(C105722 = YES) OR (C105723 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01643,NCT02567422,A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01644,NCT02567435,"A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)",Inclusion,Lansky performance status score >= 50 for patients =< 16 years of age; Karnofsky performance status score >= 50 for patients > 16 years of age,,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2015-01681,NCT02572453,"Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01706,NCT02749903,A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01707,NCT02761057,"A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)",Inclusion,Patients must have a Zubrod performance status of 0 â€“ 1,,(C19998 = YES) OR (C19999 = YES),NCI-2015-01744,NCT02581930,A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01745,NCT02797470,"A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells",Inclusion,Karnofsky performance status of 70-100%; Eastern Cooperative Oncology Group (ECOG) performance status =< [2],,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2015-01779,NCT02589522,Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-01906,NCT02595866,Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01907,NCT02595879,Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2015-01910,NCT02595892,Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES),NCI-2015-01911,NCT02734537,Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing,Inclusion,Patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 2 weeks prior to randomization,,(C105722 <= 14 d) OR (C105723 <= 14 d) ,NCI-2015-01912,NCT02595905,Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer,Inclusion,Patients must have a performance status of 0-2 by Zubrod criteria,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES),NCI-2015-01913,NCT02595918,"A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-metastatic, Renal Cell Carcinoma",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky >= 80%),,(C105722 = YES ) OR (C105723 = YES ),NCI-2015-01915,NCT02595931,Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 70%),,(C105722 = YES) OR (C105723 = YES),NCI-2015-01916,NCT02595944,Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01917,NCT02642965,"A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)",Inclusion,"Patients must have a performance status corresponding to an Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; ",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2015-01918,NCT02750826,Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-01919,NCT02717455,Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma,Inclusion,NON-PROGRESSED DIPG (STRATUM 2): Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within 7 days of enrollment must be >= 50%; ,,(C105713 <= 7 d) OR (C105712 <= 7 d) OR (C105711 <= 7 d) OR (C105710 <= 7 d) OR (C105709 <= 7 d) OR (C105707 <= 7 d) OR (C69421 <= 7 d) OR (C69422 <= 7 d) OR (C69423 <= 7 d) OR (C69424 <= 7 d) OR (C69425 <= 7 d) OR (C69426 <= 7 d),NCI-2015-01919,NCT02717455,Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma,Inclusion,RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within 7 days of enrollment must be >= 50%; ,,((C25150 > 16 a) AND (C105713 <= 7 d) OR (C105712 <= 7 d) OR (C105711 <= 7 d) OR (C105710 <= 7 d) OR (C105709 <= 7 d) OR (C105707 = YES) <= 7 d)) OR ((C25150 <= 16 a) AND (C69421 <= 7 d) OR (C69422 <= 7 d) OR (C69423 <= 7 d) OR (C69424 <= 7 d) OR (C69425 <= 7 d) OR (C69426 <= 7 d)),NCI-2015-01929,NCT02601209,A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 1,,(C105722 = YES) OR (C105723 = YES),NCI-2015-02064,NCT02627443,"Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-02125,NCT02631733,A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-02126,NCT02631746,Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%),,(C105722= YES) OR (C105723= YES) OR (C105725= YES) OR (C105712= YES) OR (C105711= YES) OR (C105710= YES) OR (C105709= YES) OR (C105707 = YES),NCI-2015-02248,NCT02890355,Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer,Inclusion,Patients must have a Zubrod performance status of 0-1,,(C19998 = YES) OR (C19999 = YES),NCI-2015-02250,NCT02642042,A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies,Inclusion,CLINICAL/LABORATORY CRITERIA: Patients must have Zubrod performance status of 0-2,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES) ,NCI-2015-02253,NCT02823652,COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Test Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling,,,,,NCI-2016-00050,NCT02785952,A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study),,,,,NCI-2016-00071,NCT03077451,A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 50%),,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES) OR (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES),NCI-2016-00150,NCT02724579,A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients,,,,,NCI-2016-00195,NCT02689453,A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL),Inclusion,Eastern Cooperative Oncology Group (ECOG) =< 1,,(C105722 = YES) or (C105723 = YES),NCI-2016-00203,NCT02713386,"A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Inclusion,"Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0, 1, or 2 within 28 days prior to registration",,((C105722 = YES ) OR ( C105723 = YES) OR (C105724 = YES )) AND ((C105722 <= 28 d ) OR C105723 <= 28 d ) OR (C105725 <= 28 d )),NCI-2016-00222,NCT02921256,A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer,Inclusion,"Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2016-00232,NCT02717507,Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial,,,,,NCI-2016-00233,NCT02927249,A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0-2,,(C105722 = YES ) OR (C105723 = YES ) OR (C105725 = YES ),NCI-2016-00252,NCT02933489,Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts,,,,,NCI-2016-00264,NCT02728596,A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER),,,,,NCI-2016-00325,NCT02728258,"A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations",Inclusion,"Performance status (Eastern Cooperative Oncology Group [ECOG]/Karnofsky) of 0, 1 or 2 within 28 days prior to registration",,(C105722 <= 28 d)  OR (C105723 <= 28 d)  OR (C105725 <= 28 d),NCI-2016-00326,NCT03055013,A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC),Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1,,(C105722 = YES ) OR (C105723 = YES),NCI-2016-00355,NCT02723864,"Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors",Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),NCI-2016-00451,NCT03091660,A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer,Inclusion,Patients must have a Zubrod performance status of 0-2,,(C19998 = YES) OR (C19999 = YES) OR (C17846 = YES),NCI-2016-00456,NCT02839343,Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1,,(C105722 = YES) OR (C105723 = YES),NCI-2016-00643,NCT02808650,"A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors",Inclusion,"Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age * Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score",,((C25150 > 16 a) AND (C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR ((C25150 <= 16 a) AND (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES)),NCI-2016-00666,NCT02775851,A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM),Inclusion,Patients must have Zubrod performance status =< 2,,(C19998 = YES)  OR (C19999 = YES) OR (C17846 = YES),NCI-2016-00667,NCT02775812,"A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)",Inclusion,Zubrod performance status of 0-1 within 28 days prior to registration,,(( C19998 = YES ) OR (C19999 = YES )) AND (( C19998 <= 28 d ) OR (C19999 <= 28 d )),NCI-2016-00708,NCT02780804,"A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",Inclusion,"Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score",,(C105713 = YES) OR (C105712 = YES) OR (C105711 = YES) OR (C105710 = YES) OR (C105709 = YES) OR (C105707 = YES) OR (C69421 = YES) OR (C69422 = YES) OR (C69423 = YES) OR (C69424 = YES) OR (C69425 = YES) OR (C69426 = YES),NCI-2016-00787,NCT03030417,A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas,Inclusion,Eastern Cooperative Oncology Group (ECOG) performance status =< 2,,(C105722 = YES) OR (C105723 = YES) OR (C105725 = YES),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,